A Study of Anlotinib in Subjects With Advanced Malignancy
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Anlotinib is a tyrosine kinase inhibitors (TKI) with high effective in inhibiting
angiogenesis and tumor cell proliferation by targeting VEGFR, PDGFR, FGFR and c-Kit. Previous
phase I trial has shown the potency of anlotinib in treating patients with various cancer
types who failed in standard treatment or lack proper treatment regimen. Here, a single
center, single-arm, phase II study was conducted to further validate the efficacy and safety
of anlotinib in these patients.